Once an unstoppable highflier, NVO is now down 45% from its mid-2015 high.
One year ago, NVO was forced to lower its long-term guidance due to increasing competition and pricing pressure in the T2D market (#msg-120272400).
NVO has been discussed on this board on various occasions as a way to participate in 'TGDT' with respect to the worldwide epidemic in type-2 diabetes. The valuation is now a lot cheaper.